Role of the Functional Toll-Like Receptor-9 Promoter Polymorphism (-1237T/C) in Increased Risk of End-Stage Renal Disease

Citation for published version:
Yang, H-Y, Su, S-L, Lu, K-C, Lee, H-S, Huang, S-M, Lin, Y-F, Wu, C-C & Salter, DM 2013, 'Role of the Functional Toll-Like Receptor-9 Promoter Polymorphism (-1237T/C) in Increased Risk of End-Stage Renal Disease: A Case-Control Study' PLoS One, vol 8, no. 3, e58444. DOI: 10.1371/journal.pone.0058444

Digital Object Identifier (DOI):
10.1371/journal.pone.0058444

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
PLoS One

Publisher Rights Statement:
Copyright: © 2013 Yang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Role of the Functional Toll-Like Receptor-9 Promoter Polymorphism (-1237T/C) in Increased Risk of End-Stage Renal Disease: A Case-Control Study

Hsin-Yi Yang, Kuo-Cheng Lu, Herng-Sheng Lee, Shih-Ming Huang, Yuh-Feng Lin, Chia-Chao Wu, Donald M. Salter, Sui-Lung Su

1 School of Public Health, National Defense Medical Center, Taipei, Taiwan, Republic of China, 2 Division of Nephrology, Department of Medicine, Cardinal Tien Hospital, School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan, Republic of China, 3 Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China, 4 Department of Biochemistry, National Defense Medical Center, Taipei, Taiwan, Republic of China, 5 Division of Nephrology, Department of Medicine, Shuang Ho Hospital, Graduate Institute of Clinical Medicine, Taipei Medical University, New Taipei City, Taiwan, Republic of China, 6 Division of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China, 7 Center for Molecular Medicine, MRC IGMM, University of Edinburgh, Edinburgh, United Kingdom

Abstract

Inflammation induced by infectious and noninfectious triggers in the kidney may lead to end stage renal disease (ESRD). Toll-like receptor 9 (TLR-9) a receptor for CpG DNA is involved in activation of immune cells in renal disease and may contribute to chronic inflammatory disease progression through an interleukin-6 (IL-6) dependent pathway. Previous studies indicate that -1237T/C confers regulatory effects on TLR-9 transcription. To date the effect of TLR-9 polymorphisms on ESRD remains unknown. We performed a case-control study and genotyped 630 ESRD patients and 415 controls for -1237T/C, -1486T/C and 1635G/A by real-time PCR assays and assessed plasma concentration of IL-6 by ELISA. Haplotype association analysis was performed using the Haploview package. A luciferase reporter assay and real-time PCR were used to test the function of the -1237T/C promoter polymorphism. A significant association between -1237T/C in TLR-9 and ESRD was identified. The TCA, TTA and CCA haplotype of TLR-9 were associated with ESRD. ESRD patients carrying -1237TC had a higher mean plasma IL-6 level when compared with -1237TT. The TLR-9 transcriptional activity of the variant -1237CC allele is higher than the -1237TT allele. The results indicate that in a Han Chinese population the presence of the C allele of -1237T/C in the TLR-9 gene increases susceptibility towards development of ESRD. In vitro studies demonstrate that -1237T/C may be involved in the development of ESRD through transcriptional modulation of TLR-9.

Citation: Yang H-Y, Lu K-C, Lee H-S, Huang S-M, Lin Y-F, et al. (2013) Role of the Functional Toll-Like Receptor-9 Promoter Polymorphism (-1237T/C) in Increased Risk of End-Stage Renal Disease: A Case-Control Study. PLoS ONE 8(3): e58444. doi:10.1371/journal.pone.0058444

Editor: Qing-Yi Wei, The University of Texas MD Anderson Cancer Center, United States of America

Received October 5, 2012; Accepted February 4, 2013; Published March 5, 2013

Copyright: © 2013 Yang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by grants from the National Science Council, National Defense Medical Center, Tri-Service General Hospital and Cardinal Tien Hospital, Taiwan, ROC (NSC99-2314-B-016-001, NSC 99-2815-C-016-002-B, TSGH-C100-007-009-10-503, CTH- NC10007, MAB101-29). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: a131419@gmail.com

Introduction

In Taiwan chronic kidney disease (CKD) is a major public health problem due to its high prevalence, high rates of healthcare utilization, high risk of progression to end-stage renal disease (ESRD) and poor prognosis [1]. The rising tide of CKD not only adds burden to global health-care resources but also has major impact on patients and their families. CKD is classified as a multifactorial disease as a combination of genetic and environmental factors influence the onset and development of ESRD [2,3]. It is now recognized that inflammation may be established before the onset of renal disease and could be a causal factor in the development of CKD. Sensors of the innate immune system, including Toll-like receptors (TLRs), provide danger recognition platforms on immune and renal cells. These can integrate and translate the diverse triggers of renal inflammation by regulating cell activation and production of proinflammatory cytokines and chemokines [4–6].

Mammalian TLRs comprise a large family of at least 11 members. Members of the TLR family play an important role in both innate and adaptive immune responses. Their genes have been found to be polymorphic [7]. TLRs recognize a wide variety of pathogen associated molecular patterns (PAMPs) from bacteria, viruses and fungi as well as some host molecules. TLR-9, expressed within the endosomal compartment, recognizes unmethylated CpG motifs present in bacterial DNA and intracellular viral antigens [6]. Recent studies have suggested roles for TLR-9 in the development of renal diseases such as glomerulonephritis [9] and lupus nephritis [10]. Single nucleotide polymorphisms (SNPs) in TLR genes affect the susceptibility to and severity of inflammatory diseases by influencing the function of these receptors. The profile of currently known genetic polymorphisms in TLR-9 has been proposed to associate with severe clinical phenotypes [11,12] and TLR-9 polymorphisms appear to affect IgA nephropathy progression [13].
In a human embryonic kidney cell line (HEK293) model system the ability to respond to physiological and therapeutic TLR-9 ligands depends on TLR-9 SNPs [14]. -1237T/C confers regulatory effects on TLR-9 transcription [15]. Indeed the C allele of the -1237T/C polymorphism generates several regulatory sites, including an IL-6-responsive element [16] and was associated with chronic renal disease in a limited candidate gene study [17]. The affect of TLR-9 polymorphisms on ESRD however remains unknown. Therefore we investigated the predictive value of TLR-9 gene polymorphisms on ESRD in a Han Chinese population and undertook in vitro experiments to study potential mechanisms of any associations.

Methods

Study Subjects
This case-control study included 630 ESRD patients (325 females and 305 males; age 64.62±14.51 years) recruited from the Cardinal Tien Hospital and five hemodialysis centers in Taipei, Taiwan. CKD was defined according to KDOQI (Kidney Disease Outcomes Quality Initiative) definitions and estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease (MDRD) Study equation [18]. ESRD was defined as eGFR <15 ml/min/1.73 m² associated with clinical signs of uremic syndrome requiring dialysis. The enrolled patients were stable (without clinical complications), aged over 20 and had been on hemodialysis (HD) for more than 6 months. Patients with autoimmune disease, malignancy or acute or chronic infection were excluded. The causes of ESRD were diabetes mellitus in 244 patients (38.7%), chronic glomerulonephritis in 199 patients (31.6%), hypertensive nephropathy in 76 patients (12.1%), systemic nephropathy in 51 patients (8.1%) and other and unknown causes in 60 patients (9.5%). The 415 healthy control subjects (217 females and 198 males; age 74.91±7.50 years) with no history for hypertension and 13.3% for diabetes mellitus were stable (without clinical complications), aged over 20 and had been on hemodialysis (HD) for more than 6 months. Patients with autoimmune disease, malignancy or acute or chronic infection were excluded. Therefore we investigated the predictive value of TLR-9 polymorphisms on ESRD in healthy control subjects with chronic renal disease in a limited candidate gene study [17].

Expression Analysis by Real-time Quantitative Reverse Transcription Polymerase Chain Reaction
1×10⁶ PBMCs cultured as above were serum starved and treated with 100 pg/ml IL-6 for 24 hours. Total RNA was isolated using TriZOL reagent (Invitrogen Cor., Carlsbad, CA, USA). Two microgram of total RNA was reverse transcribed by use of the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) into cDNA. Real-time PCR was performed with the Maxima® SYBR green qPCR master mix (Fermentas, Glen Burnie, MD, USA), using an ABI 7500 real-time PCR system (Applied Biosystems). Primer sequences were as follows: TLR-9 forward 5'-CCCCGCTACTGGTGCTATCC-3' and reverse 5'-CCCTTGCTCCTTACACTCTCC-3'; β-actin forward 5'-AGTGGCGTTCACCCCTTCTTG-3' and reverse 5'-TGACCTCTACGGTCGTTTTT-3'. Thermocycling was performed at 95°C for 10 min, 40 cycles of 95°C for 15 s and 60°C for 60 s to measure the fluorescence signal. The dissociation stages, melting curves and quantitative analyses of the data were performed using 7500 system software v1.2.3 (Applied Biosystems). Expression of β-actin was used as internal control. TLR-9 gene expression normalized by β-actin was calculated by using the 2⁻ΔΔCt method.

Transgenic Transfection and Luciferase Assay
Two TLR-9 reporter promoters (from 52260706 to 52268040, 135 bp), TLR-9-1237TTT-LUC and TLR-9-1237CC-LUC, were amplified by PCR from human genomic DNA including the SNP of interest (-1237T/C) and subcloned into a pGL3 basal reporter cut at Xhol and HindIII sites. The 5’ and 3’ primers used for PCR were: 5’-CCGCCTCGAATGGAGCACAGATACTAGGA-3’ and 5’-CGCTCTCGCTTGCATGGATG-3’. HEK293 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% charcoal/dextran-treated fetal bovine serum. The cells in each well (24-well plate) were transfected with jetPEI (PolyPlus-transfection, Illkirch, France) according to the manufacturer’s protocol; total DNA was adjusted to 1.0 μg by addition of the pGL3 reporter. 24 hours post transfection HEK293 cells were treated with IL-6 (5 ng/ml) for an additional 18 hours. Luciferase activity was assessed using the Promega Luciferase Assay kit and expressed as mean relative light units (RLU) of two transfected sets. Results shown are representative of at least three independent experiments.
Results

Demographic Characteristics

The characteristics of the 1,045 subjects are presented in Table 1. There was no significant difference in gender and diastolic blood pressure between the two groups. Significant differences in age, BMI, smoking history, systolic blood pressure, fasting blood sugar, eGFR, BUN, serum creatinine, total cholesterol and triglycerides were observed between ESRD patients and controls (P<0.001).

Association Analyses of TLR-9 Gene Polymorphisms with Susceptibility to ESRD

The distributions of TLR-9 -1237T/C, -1486T/C and 1635G/A genotypes and allele frequencies were compared between ESRD patients and controls (Table 2). The genotypic distributions of the gene polymorphisms in the patients and controls fit the Hardy-Weinberg equilibrium. The genotype and allelic distributions of TLR-9 -1237T/C were significantly different between the patients and healthy controls (adjusted OR = 4.49, 95% CI = 1.75–11.49, P = 0.002 and adjusted OR = 4.36, 95% CI = 1.72–11.08, P = 0.002, respectively). There were no significant differences of genotypic and allelic frequencies in either the TLR-9 -1486T/C or 1635G/A between ESRD patients and controls. The dominant genetic models showed that -1486T/C may be a protective factor for ESRD (adjusted OR = 0.71, 95% CI = 0.53–0.97, P = 0.03).

Although a higher eGFR was observed for patients with the TLR-9 -1237TT genotype this did not reach statistical significance and overall there was no significant association between TLR-9 -1237T/C and the degree of renal function in the ESRD group (results not shown). Stratifying patients by the underlying cause of their renal disease demonstrated marginal associations with genotype and both glomerulonephritis (P = 0.04) and hypertension (P = 0.03) but not with diabetic (P = 0.08) or systemic nephropathy (P = 0.13) (results not shown).

Haplotype Analysis of TLR-9

The haplotype analysis of TLR-9 polymorphisms in ESRD patients and control subjects is shown in Table 3. The frequency of haplotype “TCA” was 27.8% in the ESRD patients compared to 34.6% in the controls (OR = 0.73, 95% CI = 0.60–0.88, P = 0.001). In contrast haplotypes TTA and CCA were more common in ESRD patients (6.3% and 2.5%, respectively) than in controls (1.9% and 0.6%, respectively) (OR = 3.47 and 4.45, 95% CI = 2.02–5.97 and 1.70–11.67, P<0.001 and <0.001, respectively). Other haplotypes showed no significant difference (Table 3).

Association of TLR-9 -1237 T/C Polymorphism with Plasma IL-6 Level

We evaluated whether the TLR-9 -1237 T/C polymorphism might be associated with IL-6 levels in the plasma of ESRD patients. Data are shown in figure 1. Compared to healthy controls (1.56±0.24 pg/ml) the ESRD patients (4.54±0.38 pg/ml) showed a significantly higher level of plasma IL-6 (P<0.001, figure 1A). The plasma IL-6 level did not differ significantly in healthy controls between different TLR-9 -1237T/C genotypes (TT: 1.53±0.10 pg/ml; TC: 1.60±0.11 pg/ml; P = 0.87, figure 1B). The ESRD patients carrying -1237TC had a higher mean plasma IL-6 level (5.47±0.36 pg/ml) when compared with -1237TT (3.71±0.40 pg/ml; P = 0.01, figure 1C). No significant association was shown for other TLR-9 polymorphisms with plasma IL-6 concentration (results not shown).

TLR-9 mRNA Expression in PBMCs

The results of TLR-9 gene expression among 32 ESRD patients are shown in figure 2. Under basal conditions and following IL-6 treatment there was no significant difference in the expression of TLR-9 mRNA between the TT (n = 18) and TC (n = 14) genotypes (basal condition, TT = 1.09±0.09, TC = 1.21±0.25; IL-6 treatment, TT = 1.04±0.00, TC = 1.08±0.21, mean ± SEM relative mRNA expression). Similar results were seen in samples from healthy controls (TT = 8, TC = 7) (results not shown). Under basal conditions or following IL-6 treatment there was no significant difference in the expression of TLR-9 mRNA between the genotypes (mean ± SEM relative mRNA expression: basal condition, TT = 1.12±0.15, TC = 1.19±0.18; IL-6 treatment: TT = 1.08±0.19, TC = 1.16±0.21).

Comparison of Promoter Activity of TT and CC Alleles of the TLR-9 Promoter -1237T/C

To establish whether the TLR-9 SNPs were functionally important we investigated whether IL-6 influenced TLR-9 mRNA expression were assessed by the Kruskal-Wallis (K-W) test.

Table 1. Clinical and biochemical parameters in ESRD patients and control subjects.

|                     | Patients n = 630 | Controls n = 415 | P value |
|---------------------|-----------------|-----------------|---------|
| Male (%)            | 48.4            | 47.6            | 0.80    |
| Age (yrs)           | 64.62±14.51     | 74.91±7.50      | <0.001  |
| Body mass index (kg/m²) | 21.71±5.39     | 24.18±3.11      | <0.001  |
| Current or former smoker (%) | 22.8 | 14.0            | <0.001  |
| Systolic blood pressure (mmHg) | 140.86±33.25  | 129.14±15.64    | <0.001  |
| Diastolic blood pressure (mmHg) | 75.39±10.84   | 75.14±11.96     | 0.72    |
| Fasting plasma glucose (mg/dL) | 143.76±56.94 | 102.56±22.59    | <0.001  |
| eGFR (mg/dL)        | 7.81±3.83       | 8.46±4.60       | <0.001  |
| BUN (mg/dL)         | 65.53±19.10     | 64.27±5.22      | <0.001  |
| Serum creatinine (mg/dL) | 9.40±2.60     | 0.86±0.32       | <0.001  |
| Serum total cholesterol (mg/dL) | 166.49±33.38 | 187.44±32.98    | <0.001  |
| Serum triglycerides (mg/dL) | 152.33±95.92 | 116.50±58.55    | <0.001  |

Quantitative data are mean ± SD. doi:10.1371/journal.pone.0058444.t001
promoter activity using a luciferase reporter assay in HEK293 cells. The results are shown in figure 3. The luciferase activity of the C allele was significantly higher in the absence (10.50 ± 1.06) and presence of IL-6 (11.15 ± 0.16) in comparison to that of the T allele (basal condition 5.61 ± 0.29 and following IL-6 treatment 6.61 ± 0.12) (P = 0.01). However there was no significant difference in TLR-9 promoter activity between -1237TT and -1237TC following IL-6 treatment (P = 0.10 and 0.49, respectively).

Based on a previous study by our group [17] we have examined possible associations between three TLR-9 SNPs and ESRD in a Han Chinese population. Furthermore, in view of the known interactions between TLR-9 and IL-6 we also studied the association between TLR-9 -1237T/C and plasma IL-6 levels in ESRD and performed functional studies using this SNP. Our study has shown a statistically significant association between a polymorphism in the promoter of TLR-9 gene (-1237T/C) and ESRD. A weaker association between TLR-9 -1486T/C and ESRD was seen in dominant genetic models. The study groups were matched for sex but there were significant differences in BMI, smoking status and age between ESRD patients and healthy controls. Indeed it is recognized that patients with ESRD are often malnourished [22,23] and malnourishment is associated with poor survival in these patients [24]. We have used a non-matched case-control design and applied multiple logistic regression to adjust for confounders. Interestingly a study analyzing the quality of life of irritable bowel syndrome patients compared results when groups were matched and non-matched and found identical results. Indeed the matching procedure slightly diminished the statistical power of the results [25]. In the current study the frequency of TLR9 -1237T/C was 1%. The allele frequency of this SNP in the Han Chinese population (0.007–0.03) [17,26,27] is significantly different from Caucasians (0.10–0.15) and African Americans.

### Table 2. Genotype distributions and allele frequencies for the TLR-9 gene in ESRD patients and control subjects.

| Genotypes | Patients n or (%) | Controls n or (%) | Crude OR (95% CI) | P value | Adjusted OR (95% CI) | P value |
|-----------|------------------|------------------|-------------------|---------|---------------------|---------|
| T-1237C   |                  |                  |                   |         |                     |         |
| TT        | 591              | 408              | 1                 | <0.001  |                     |         |
| TC        | 39               | 7                | 3.85 (1.70–8.68)  | 0.001   | 4.49 (1.75–11.49)   | 0.002   |
| Alleles   |                  |                  |                   |         |                     |         |
| T-allele  | 97%              | 99%              | 1                 |         | 1                   |         |
| C-allele  | 3%               | 1%               | 3.76 (1.67–8.44)  | 0.001   | 4.36 (1.72–11.08)   | 0.002   |
| T-1486C   |                  |                  |                   |         |                     |         |
| TT        | 276              | 155              | 1                 | 0.10    |                     |         |
| TC        | 290              | 208              | 0.78 (0.60–1.02)  | 0.07    | 0.72 (0.52–1.00)    | 0.05    |
| CC        | 64               | 52               | 0.69 (0.46–1.05)  | 0.08    | 0.68 (0.41–1.13)    | 0.14    |
| Alleles   |                  |                  |                   |         |                     |         |
| T-allele  | 67%              | 62%              | 1                 |         | 1                   |         |
| C-allele  | 33%              | 38%              | 0.82 (0.69–0.99)  | 0.04    | 0.80 (0.64–1.00)    | 0.05    |
| G1635A    |                  |                  |                   |         |                     |         |
| GG        | 245              | 158              | 1                 | 0.90    |                     |         |
| GA        | 306              | 206              | 0.96 (0.73–1.25)  | 0.75    | 0.94 (0.68–1.30)    | 0.72    |
| AA        | 79               | 51               | 1.00 (0.67–1.50)  | 0.99    | 0.97 (0.59–1.58)    | 0.90    |
| Alleles   |                  |                  |                   |         |                     |         |
| G-allele  | 63%              | 63%              | 1                 |         | 1                   |         |
| A-allele  | 37%              | 37%              | 0.99 (0.82–1.19)  | 0.90    | 0.97 (0.78–1.21)    | 0.81    |
| *D model | 276/354          | 155/260          | 0.77 (0.59–0.99)  | 0.04    | 0.71 (0.53–0.97)    | 0.03    |
| *R model | 566/64           | 363/52           | 0.79 (0.54–1.17)  | 0.23    | 0.81 (0.51–1.30)    | 0.39    |

*Data are expressed as n or (%) and have been adjusted by gender, age, BMI, and smoking status.

**D model = Dominant model.

**R model = Recessive model.

**Table 3. Haplotype frequencies in TLR-9 of ESRD patients and control subjects.

| Haplotypes | Frequencies | Patients Controls P value OR (95% CI) |
|-----------|-------------|------------------------------------|
| T-1237C   | T-1486C G1635A | Patients Controls P value OR (95% CI) |
| T          | T           | 0.603 0.603 0.90 1.00 (0.83–1.19) |
| T          | C           | 0.278 0.346 0.001 0.73 (0.60–0.88) |
| T          | T           | 0.065 0.019 <0.001 3.47 (2.02–5.97) |
| T          | C           | 0.023 0.023 0.90 1.02 (0.57–1.83) |
| C          | C           | 0.025 0.006 <0.001 4.45 (1.70–11.67) |

**Discussion**

Based on a previous study by our group [17] we have examined possible associations between three TLR-9 SNPs and ESRD in a Han Chinese population. Furthermore, in view of the known interactions between TLR-9 and IL-6 we also studied the association between TLR-9 -1237T/C and plasma IL-6 levels in ESRD and performed functional studies using this SNP. Our study has shown a statistically significant association between a polymorphism in the promoter of TLR-9 gene (-1237T/C) and ESRD. A weaker association between TLR-9 -1486T/C and ESRD was seen in dominant genetic models. The study groups were matched for sex but there were significant differences in BMI, smoking status and age between ESRD patients and healthy controls. Indeed it is recognized that patients with ESRD are often malnourished [22,23] and malnourishment is associated with poor survival in these patients [24]. We have used a non-matched case-control design and applied multiple logistic regression to adjust for confounders. Interestingly a study analyzing the quality of life of irritable bowel syndrome patients compared results when groups were matched and non-matched and found identical results. Indeed the matching procedure slightly diminished the statistical power of the results [25]. In the current study the frequency of TLR9 -1237T/C was 1%. The allele frequency of this SNP in the Han Chinese population (0.007–0.03) [17,26,27] is significantly different from Caucasians (0.10–0.15) and African Americans.
This indicates the existence of a geographic/ethnic-specific difference in TLR-9 genotypes that may in part reflect ethnic diversity to ESRD susceptibility or other conditions where TLR-9 pathways may be involved.

There is emerging evidence that TLR-9 may play an important role in renal disease and a number of inflammatory conditions of other organ systems. Activation of TLR-9 induces progression of renal disease in MRL-Fas (lpr) mice [30]. TLR-9 has been shown to be involved in antigen-induced immune complex glomerulonephritis and lupus nephritis through regulation of both humoral and cellular immune responses [31]. With respect to TLR-9 SNPs, the -1237T/C polymorphism has been shown to be associated with asthma [29], Crohn’s disease [32] and HIV infection [33]. The TLR-9 2848 AA genotype is associated with significantly higher expression of TLR-9 and the frequency of intracellular IgM positive B cells in patients with Primary Biliary Cirrhosis [34] whilst the TLR-9 1635G/A polymorphism appears to play a role in the susceptibility to Systemic lupus erythematosus (SLE) in a Chinese population [35]. Less is known regarding TLR-9 SNPs and renal disease. We have previously identified an association between CKD and the -1237T/C of TLR-9 [17] whilst another group has shown that +1174A/G is associated with increased risk for progression of IgA nephropathy in Japanese patients [36] and patients with a TT genotype at 1635G/A show more severe renal damage and poorer therapeutic outcomes [37].

The haplotype of three polymorphisms in TLR-9 was associated with ESRD in the current study. Our data indicate that ESRD

Figure 1. Effects of TLR-9 -1237T/C genotype on the level of plasma IL-6 in healthy controls and ESRD patients. IL-6 concentration was quantified by ELISA. Results are expressed as mean ± SEM. The columns represent the mean value and the lines represent standard error of mean. A: Compared to the healthy controls, the ESRD patients showed a significant increase in plasma IL-6 level (P<0.001). B: The difference of mean level of IL-6 between TT (n = 22) and TC (n = 7) carriers was not significant (P = 0.87) in healthy controls. C: The difference of mean level of IL-6 between TT (n = 18) and TC (n = 14) carriers showed significant difference (P = 0.01) in ESRD patients. *P<0.05.

doi:10.1371/journal.pone.0058444.g001

Figure 2. Comparison of PBMC TLR-9 mRNA expression between different genotypes of -1237T/C. β-actin gene expression was used as an internal control gene. TLR-9 mRNA expression in TT or TC PBMCs in the absence or presence of IL-6 (100 pg/ml) treatment was assessed. Values shown are mean ± SEM. Experiments were performed in triplicate.

doi:10.1371/journal.pone.0058444.g002

Figure 3. Effects of the -1237T/C genotype in TLR-9 promoter on luciferase activity in cultured HEK293 cells. Luciferase reporters containing a TLR-9 promoter sequence with the wild-type T allele or risk C allele at SNP -1237T/C were transfected into HEK293 cells. The mean ± SEM is given for each construct from three experiments. *P<0.05.

doi:10.1371/journal.pone.0058444.g003
patients carrying the TCA haplotype had a lower risk of ESRD than those not carrying this haplotype whilst patients carrying the TTA or CCA haplotype had a higher risk of ESRD than those not carrying these haplotypes. Holla et al. (2009) demonstrated previously that the TLR-9 TTA haplotype may increase susceptibility to chronic periodontitis whereas the TLR-9 TCG haplotype has a protective effect against this condition [39]. Specific haplotypes in the TLR-9 gene might affect host defense mechanisms and influence susceptibility or resistance to infections. Common TLR-9 alleles with a frequency higher than 5% however do not appear to contribute significantly to the genetic risk involved in susceptibility to SLE or lupus nephritis [39]. Further work is required to fully understand the role of TLR-9 haplotypes on the genetic susceptibility to ESRD.

TLR-9 has been mapped to chromosome 3p21.3. It spans approximately 5 kb and has two exons, the second of which is the major coding region. To date several transcription factors such as AP-1, Sp-1, NF-kB, GATA and CRE are recognized to regulate expression of the TLR-9 gene [40]. In the current study we assessed the functionality of the TLR-9 -1237T/C polymorphism for effects on transcriptional activity. Our data suggest that transcriptional activity of the variant C allele is higher than that of the wild-type T allele. This may be a consequence of creation of an NF-kB binding site with the C allele [41]. Indeed higher transcriptional activity was seen in the presence of the CC allelic variant. These results are consistent with observations of a moderate increase in promoter activity associated with the -1237CC genotype of TLR-9 in asthma patients [15]. Higher promoter activity of the TT allelic variant at -1237T/C in atopic eczema [42] may relate to different pathogenetic mechanisms and indicate the need for further investigation in this area. In silico analysis of the human TLR-9 promoter reveals that the C allele of the -1237T/C polymorphism generates several new regulatory sites including an IL-6-responsive element [16]. In the study of Carvalho et al. (2011) PBMCs containing the TC allele but not those with the TT allele increased TLR-9 gene expression in response to IL-6 [16]. In contrast no association between -1237T/C genotype and TLR-9 mRNA level or promoter activity following IL-6 treatment was identified in the current study. The reason for this discrepancy is not clear but differences in cell sources, detection methods, and time course of experiments in addition to the complexity of gene regulation in vivo may be relevant.

IL-6 is a pleiotropic cytokine that plays a central role in modulating inflammatory responses. Several studies have indicated that IL-6 is a reliable predictor of mortality in ESRD [33,44]. B-cell activation with a TLR-9 agonist significantly increases production of IL-6 in ESRD patients when compared to normal age-matched controls [45]. Associations between genetic polymorphisms and plasma IL-6 levels have been identified [46]. SNPs in the IL-6 gene are associated with plasma IL-6 in myocardial infarction survivors [47] and IL-6 plasma levels are modulated by a polymorphism in the NF-kB1 gene [48]. Our data revealing that ESRD patients carrying -1237TC in TLR-9 gene had a higher mean plasma IL-6 level than those carrying -1237TT are consistent with previous observations [16]. SNPs in the promoter region affecting TLR-9 transcriptional activity might explain inter-individual variability in the production of IL-6 in ESRD patients. However whether a TLR-9/-IL-6 signal amplification loop such as that which regulates B cell proliferation [16] is active in patients with renal disease remains to be investigated.

In conclusion, we found the -1237T/C SNP of the TLR-9 gene is significantly associated with ESRD in a Han-Chinese population and that -1237T/C may be involved in the development of ESRD through transcriptional modulation of TLR-9. These observations provide new insights into the role of TLR-9 polymorphisms in renal disease that have the potential to provide new avenues for treatment and may also allow identification of individuals at risk.

Author Contributions

Conceived and designed the experiments: HYY KCL HSL DMS SLS. Performed the experiments: HYY KCL SMH YFL CCW. Analyzed the data: HYY HSI SMH YFL CCW SLS. Contributed reagents/materials/analysis tools: KCL HSL SMH YFL SLS. Wrote the paper: HYY HSI SMH DMS SLS.

References

1. Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, et al. (2008) All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462,293 adults in Taiwan. Lancet 371: 2173–2182.

2. Sun TH, Spidlen JG, Sercarz EE, Fyve DG, Freedman BI (2007) Familial clustering of chronic kidney disease. Semin Dial 20: 229–236.

3. Adler S (2006) Renal disease: environment, race, or genes? Ehra Dis 16: S2–33–39.

4. ElEFteriadi TS, Lawson BR. (2009) Toll-like receptors and kidney diseases. Inflamm Allergy Drug Targets 8: 191–201.

5. Smith KD (2009) Toll-like receptors in kidney disease. Curr Opin Nephrol Hypertens 18: 189–196.

6. Koe M, Toprak A, Arik H, Odabasi Z, Elbir Y, et al. (2011) Toll-like receptor expression in monocytes in patients with chronic kidney disease and haemodialysis: relation with inflammation. Nephrol Dial Transplant 26: 953–963.

7. Schwartz DA, Cook DN (2005) Polymorphisms of the Toll-like receptors and human disease. Clin Infect Dis 41 Suppl 7: S405–407.

8. Dalpke A, Zimmermann S, Heeg K (2002) CpG DNA in the prevention and treatment of infections. Bio Drugs 16: 419–431.

9. Summers SA, Steimmetz OM, Osa JD, Gaz PV, O’Sullivan KM, et al. (2010) Toll-like receptor 9 enhances nephroinflammatory immunity and glomerular leukocyte recruitment, exacerbating experimental crescentic glomerulonephritis. Am J Pathol 177: 2234–2244.

10. Summers SA, Hej J, Steimmetz OM, O’Sullivan KM, Osa JD, et al. (2010) TLR3 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy. J Autoimmun 35: 293–298.

11. Bochud PY, Hersberger M, Taffe P, Bochud M, Stein CM, et al. (2007) Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV infection. AIDS 21: 441–446.

12. Kreyenberg PA, Hersberger M, Truminger K, Mullhaupt B, Maly FE, et al. (2010) Toll-like receptor 4 gene polymorphism modulates phenotypic expression in patients with hereditary hemochromatosis. Eur J Gastroenterol Hepatol 22: 835–841.

13. Suzuki H, Suzuki Y, Narita I, Aizawa M, Kihara M, et al. (2008) Toll-like receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol 19: 2304–2309.

14. Kubarenko AV, Ranjan S, Rautanen A, Mills TC, Wong S, et al. (2010) A naturally occurring variant in human TLR9, P99L, is associated with loss of CpG oligonucleotide responsiveness. J Biol Chem 285: 36486–36499.

15. Lange NE, Zhou X, LaskySu J, Hines BE, Lazarus R, et al. (2011) Comprehensive genetic assessment of a functional TLR9 promoter polymorphism: no replicable association with asthma or asthma-related phenotypes. BMC Med Genet 12: 26.

16. Carvalho A, Oostro NS, Saravia M, Cunha C, Almeida AJ, et al. (2011) The C allele of rs5743836 polymorphism in the human TLR9 promoter links IL-6 and TLR9 up-regulation and confers increased B-cell proliferation. PLoS One 6: e20236.

17. Lu KG, Yang HY, Lin YF, Kao SY, Lai CH, et al. (2011) The T-1237C polymorphism of the Toll-like receptor-9 gene is associated with chronic kidney disease in a Han Chinese population. Tohoku J Exp Med 225: 109–116.

18. Levey AS, Bosch JP, Lewis JB, Rogers N, et al. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461–470.

19. Hamann L, Hamperecht A, Gonna A, Schumann RR (2004) Rapid and inexpensive real-time PCR for genotyping functional polymorphisms within the Toll-like receptor -2, -4, and -9 genes. J Immunod Methods 285: 281–291.

20. Bello-Pizarro-Pizarro N, Vallejo A, Ramirez-Lorca R, Rodriguez-Med M, Salinas A, et al. (2008) Influence of the Toll-like receptor 9 963G/A polymorphism on the CD4 count, HIV viral load, and clinical progression. J Acquir Immune Defic Syndr 49: 126–135.
32. Toörkö T, Glas J, Endres I, Tsonenchi L, Teshome MY, et al. (2009) Epistasis
31. Anders HJ, Banas B, Schlondorff D (2004) Signaling danger: toll-like receptors
30. Anders HJ, Vielhauer V, Eis V, Linde Y, Kretzler M, et al. (2004) Activation of
29. Lazarus R, Klimecki WT, Raby BA, Vercelli D, Palmer LJ, et al. (2003) Single-
28. Velez DR, Wejse C, Stryjewski ME, Abbate E, Hulme WF, et al. (2010) Variants
27. Wu JF, Chen CH, Ni YH, Lin YT, Chen HL, et al. (2012) Toll-like receptor and
26. Ng MW, Lau CS, Chan TM, Wong WH, Lau YL (2005) Polymorphisms of the
25. Faresjo T, Faresjo A (2010) To match or not to match in epidemiological
24. Jansen MA, Korevaar JC, Dekker FW, Jager KJ, Boeschoten EW, et al. (2001)
23. Gama-Axelsson T, Heimburger O, Stenvinkel P, Barany P, Lindholm B, et al. (2004) Toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J 18: 534–536.
22. Kopple JD, Greene T, Chumlea WC, Hollinger D, Maroni BJ, et al. (2000) Relationship between Toll-like receptor-9 polymorphisms and variants in NOD2 and IL23R and their potential roles in kidney disease. J Am Soc Nephrol 15: 854–867.
21. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263–265.
20. Koppel JD, Greene T, Chumlea WC, Hollinger D, Maroni BJ, et al. (2000) Relationship between nutritional status and the glomerular filtration rate: results from the MDRD study. Kidney Int 57: 1608–1703.
19. Gama-Axelson T, Heimburger O, Stenvinkel P, Barany P, Lindholm B, et al. (2012) Serum albumin as predictor of nutritional status in patients with ESRD. Clin J Am Soc Nephrol 7: 1446–1453.
18. Jansen MA, Korevaar JC, Dekker FW, Jager KJ, Boeschoten EW, et al. (2001) Renal function and nutritional status at the start of chronic dialysis treatment. J Am Soc Nephrol 12: 157–163.
17. Faresjo T, Faresjo A (2010) To match or not to match in epidemiological studies—same outcome but less power. Int J Environ Res Public Health 7: 325–332.
16. Ng MW, Lau CS, Chan TM, Wong WH, Lau YL. (2005) Polymorphisms of the toll-like receptor 9 (TLR9) gene with systemic lupus erythematosus in Chinese. Rheumatology (Oxford) 44: 1436–1437.
15. Wu JF, Chen CH, Ni YH, Lin YT, Chen HL, et al. (2012) Toll-like receptor-9 polymorphisms and variants in NOD2 and IL23R and their potential roles in kidney disease. J Am Soc Nephrol 15: 854–867.
14. Takeshita F, Suzuki K, Sasaki S, Ishi N, Kliman DM, et al. (2004) Transcriptional regulation of the human TLR9 gene. J Immunol 173: 2523–2531.
13. De Jager PL, Richardson A, Vyse TJ, Rioux JD (2006) Genetic variation in toll-like receptor 9 and susceptibility to systemic lupus erythematosus among Chinese. Mol Biol Rep 36: 2245–2248.
12. Sato D, Suzuki Y, Kano T, Suzuki H, Matsuo A, et al. (2012) Toll-like receptor 9 expression and efficacy of tolstalectomy with steroid pulse therapy in IgA nephropathy patients. Nephrol Dial Transplant 27: 1090–1097.
11. Holla LJ, Vokurka J, Hrstlikova B, Augustin P, Fasmann A (2009) Association of Toll-like receptor 9 haplotypes with chronic periodontitis in Czech population. J Clin Periodontol 37: 152–159.
10. De Jager PL, Richardson A, Vyse TJ, Rioux JD (2006) Genetic variation in toll-like receptor 9 and susceptibility to systemic lupus erythematosus. Arthritis Rheum 54: 1279–1282.
9. Ng MT, Van’t Hof R, Crockett JC, Hope ME, Berry S, et al. (2010) Increase in NF-kappaB binding affinity of the variant C allele of the toll-like receptor 9 -1237T/C polymorphism is associated with Helicobacter pylori-induced gastric disease. Infect Immun 78: 1345–1352.
8. Novak N, Yu CF, Bussmann C, Maintz L, Peng WM, et al. (2007) Putative association of a TLR9 promoter polymorphism with atopic eczema. Allergy 62: 766–772.
7. Hasuike Y, Nonoguchi H, Ito K, Naka M, Kitamura R, et al. (2009) Interleukin-6 is a predictor of mortality in stable hemodialysis patients. Am J Nephrol 30: 389–398.
6. Zoccali C, Tripepi G, Mallamaci F (2006) Dissecting inflammation in ESRD: Do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients? J Am Soc Nephrol 17: 8169–8173.
5. Pahl MV, Gollapudi S, Sepassi L, Gollapudi P, Elahimehr R, et al. (2010) Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. Nephrol Dial Transplant 25: 203–212.
4. Smith AJ, Humphries SE (2009) Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev 20: 43–59.
3. Ljungman P, Bellander T, Nyberg F, Lampa E, Jacquemin B, et al. (2009) DNA methylation of the TLR9 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. Leuk Lymphoma 53: 411–416.
2. Giachelia M, Voso MT, Tisi MC, Martini M, Bozzoli V, et al. (2012) Chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. Leuk Lymphoma 53: 411–416.